Halozyme Therapeutics, Inc. (HALO)
67.44
+0.32
(+0.48%)
USD |
NASDAQ |
May 18, 16:00
67.44
0.00 (0.00%)
After-Hours: 16:46
Halozyme Therapeutics Shareholders Equity (Quarterly) : 219.64M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 19.36B |
| Agenus, Inc. | -221.22M |
| Inovio Pharmaceuticals, Inc. | 6.068M |
| Curis, Inc. | 12.71M |
| LadRx Corp. | -2.135M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.673B |
| Total Liabilities (Quarterly) | 2.453B |
| Debt to Equity Ratio | 9.764 |
| Current Ratio | 2.762 |
| Net Debt Paydown Yield | -1.59% |